Abstract: OBJECTIVE To evaluate the cost-effect of 3 therapeutic schemes in treatment of posthepatitic cirrhosis with YMDD mutation. METHODS Sixty-four patients were randomly assigned into three groups. In A group, patients were administrated with adefovir dipivoxil (ADV) (10 mg·d^-1) for 48 weeks. In B group, patients were administrated with ADV(10 mg·d^-1) in combination with lamivudine (LAM) (100 mg·d^-1) during the first 12-week period and in the second period, all the patients were singly administrated with ADV (10 mg·d^-1) for 36 weeks. But in the C group, patients received ADV(10 mg·d^-1) in combination with LAM(100 mg·d^-1) for 48 weeks. The data were evaluated with cost-effectiveness analysis. RESULTS The three groups′cost-effectiveness ratios of serum alanine aminotransferase normalization rate were 15 721.8, 16 922.6, 15 140.6. As compared with group A, the incremental cost-effectiveness ratios of groups B and C were 29 064.4 and 14 412.1, respectively. The three groups′cost-effectiveness ratios of HBV-DNA negative rate were13 125.5，15 384.2，14 334.5. As compared with group A, the incremental cost-effectiveness ratios of groups B and C were 261 580.0 and 16 400.0, respectively. The three groups，cost-effectiveness ratios of HBeAg/HBeAb seroconversion rate were 43 092.8, 54 943.5, 57 873.8. As compared with group A, the incremental cost-effectiveness ratios of groups B and C were 108 992.0 and 108 991.7, respectively. One patient had rtN236T mutation and another one had rtA181V mutation after 48-week treatment in A group and one patient had rtN236T mutation in B group. CONCLUSION ADV in combination with LAM is more cost-effective in treatment of posthepatitic cirrhosis with YMDD mutation.